Ben Bronstein, Director at Aldeyra Therapeutics, Inc. (ALDX), bought 1,700 shares at $5.85 ($10K) on 2019-09-17, disclosed to the SEC on 2019-09-19.
Open-market purchase of $10k ALDX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |